Compare JUBILANT LIFE SCIENCES with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES LUPIN JUBILANT LIFE SCIENCES/
LUPIN
 
P/E (TTM) x 15.3 48.6 31.4% View Chart
P/BV x 1.8 2.5 71.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   LUPIN
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
LUPIN
Mar-19
JUBILANT LIFE SCIENCES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs898986 91.1%   
Low Rs618720 85.7%   
Sales per share (Unadj.) Rs572.0369.5 154.8%  
Earnings per share (Unadj.) Rs36.213.4 270.2%  
Cash flow per share (Unadj.) Rs59.537.4 159.2%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.9303.7 99.4%  
Shares outstanding (eoy) m159.28452.49 35.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.3 57.4%   
Avg P/E ratio x20.963.6 32.9%  
P/CF ratio (eoy) x12.722.8 55.8%  
Price / Book Value ratio x2.52.8 89.3%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,694386,064 31.3%   
No. of employees `0002.417.7 13.5%   
Total wages/salary Rs m19,26031,513 61.1%   
Avg. sales/employee Rs Th38,120.69,453.8 403.2%   
Avg. wages/employee Rs Th8,058.41,782.0 452.2%   
Avg. net profit/employee Rs Th2,414.3343.0 703.9%   
INCOME DATA
Net Sales Rs m91,108167,182 54.5%  
Other income Rs m3573,640 9.8%   
Total revenues Rs m91,466170,822 53.5%   
Gross profit Rs m17,39028,822 60.3%  
Depreciation Rs m3,70910,850 34.2%   
Interest Rs m2,1983,078 71.4%   
Profit before tax Rs m11,84018,534 63.9%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-2,802-3,400 82.4%   
Tax Rs m3,2689,017 36.2%   
Profit after tax Rs m5,7706,066 95.1%  
Gross profit margin %19.117.2 110.7%  
Effective tax rate %27.648.7 56.7%   
Net profit margin %6.33.6 174.6%  
BALANCE SHEET DATA
Current assets Rs m45,848138,536 33.1%   
Current liabilities Rs m20,89761,299 34.1%   
Net working cap to sales %27.446.2 59.3%  
Current ratio x2.22.3 97.1%  
Inventory Days Days5784 67.8%  
Debtors Days Days51112 45.3%  
Net fixed assets Rs m65,498127,516 51.4%   
Share capital Rs m159905 17.6%   
"Free" reserves Rs m47,930136,517 35.1%   
Net worth Rs m48,089137,422 35.0%   
Long term debt Rs m42,42966,417 63.9%   
Total assets Rs m114,685279,494 41.0%  
Interest coverage x6.47.0 91.0%   
Debt to equity ratio x0.90.5 182.6%  
Sales to assets ratio x0.80.6 132.8%   
Return on assets %6.93.3 212.4%  
Return on equity %12.04.4 271.8%  
Return on capital %12.48.9 139.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42259,414 20.9%   
Fx outflow Rs m17,22722,282 77.3%   
Net fx Rs m-4,80537,132 -12.9%   
CASH FLOW
From Operations Rs m11,21516,660 67.3%  
From Investments Rs m-10,118-32,825 30.8%  
From Financial Activity Rs m6,5747,441 88.3%  
Net Cashflow Rs m7,612-8,724 -87.3%  

Share Holding

Indian Promoters % 45.6 46.6 97.9%  
Foreign collaborators % 3.5 0.2 1,750.0%  
Indian inst/Mut Fund % 8.7 11.3 77.0%  
FIIs % 21.2 31.9 66.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.1 208.9%  
Shareholders   23,815 98,259 24.2%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  SANOFI INDIA  PANACEA BIOTECH  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 18, 2019 12:25 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS